SEC
File Number: 333-57946
|
|
CUSIP
Number: 45719U
10 0
|
Read
Instruction (on back page) Before Preparing Form. Please Print or
Type.
|
Nothing
in this form shall be construed to imply that the Commission has
verified
any information contained herin.
|
PART
I -- REGISTRANT INFORMATION
|
Inhibiton
Therapeutics, Inc.
Full
Name of Registrant
|
_________________________
Former
Name if Applicable
|
7315
E. Peakview Avenue
Address
of Principal Executive Office (Street
and Number)
|
Englewood,
Colorado 80111
City,
State and Zip Code
|
x
|
(a)
The reasons described in reasonable detail in Part III of this form
could
not be eliminated without unreasonable effort or expense;
(b)
The subject annual report, semi-annual report, transition report
on Form
10-KSB , Form 20-F,11-K or Form N-SAR, or portion thereof, will be
filed
on or before the fifteenth calendar day following the prescribed
due date;
or the subject quarterly report or transition report on Form 10-QSB,
or
portion thereof will be filed on or before the fifth calendar day
following the prescribed due date; and
(c)
The accountant's statement or other exhibit required by Rule 12b-25(c)
has
been attached if applicable.
|
Thomas
B. Olson
(Name)
|
(303)
(Area
Code)
|
796-8940
(Telephone
Number)
|
Date: May
1, 2007
|
By:/s/
Thomas B. Olson
Thomas
B. Olson, Secretary
|
Intentional
misstatements or omissions of fact constitute Federal Criminal Violations
(See 18 U.S.C. 1001).
|